Growing connection for Bio Ecosystems

Interconnect innovation ecosystems, share competences, information and opportunities in the biopharmaceutical deeptech sector.

Play Intro Video

What is COBIOE ?

COBIOE is a European funded project to interconnect innovation ecosystems to foster 4.0 industrial transition in the biopharmaceutical deeptech sector, sharing competences, information and opportunities, with the aim of ultimately converging toward a common and inclusive European strategy for bioproduction support.

Specifically, the proposition is focused on the bioproduction sector that includes development of small molecules, biologics, drugs, innovative therapeutics (such as gene and cellular therapies), high technology drugs based on cell and molecular biology, and covers various applications in health (oncology, immunology, virology, rare diseases, etc…).

Bioproduction value chain

To structure the European bioproduction ecosystems, we have chosen to position the different stakeholders on this value chain:

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

What is COBIOE ?

We help you build the bridges between the public and private sectors, research and production, industries and innovators, to guarantee a better access to innovative biotherapies for European citizens.

You are a start-up, company, research center

 Discover

You are an ecosystem of innovation, an institution

 Discover

You are a European citizen

 Discover

COBIOE Solutions

Discover our solutions to unlock a realm of connections, insights,
and collaborations that empower your growth.

Business pioneering

Explore a comprehensive mapping of the European bioproduction stakeholders with our advanced Interactive Map.

Gain insights into the entire value chain and access geolocated information about key players. Discover new partners and potential collaborators across Europe effortlessly.

Explore

Collaboration Hub

Forge meaningful collaborations through our powerful matchmaking feature.

Connect with like-minded innovators, researchers, and corporations to amplify your impact and drive bioproduction projects forward. Fuel your success through strategic partnerships.

Explore

Enhanced Visibility

Position your organization seamlessly within the European bioproduction Value Chain. Benefit from the Geolocated Map to showcase your expertise, projects, and initiatives.

Boost your visibility and make meaningful connections within the ecosystem.

Explore

Competitive Intelligence

Stay informed with our Competitive Intelligence area. Search by keywords or tags to access vital industry information and trends.

Create alerts to receive real-time updates that empower you to make informed decisions.

Explore

Interested ?

Register your entity to showcase your expertise, projects, and initiatives and
boost your visibility.

Register my entity

Upcoming events

Congress
Bio-Europe Spring
18/03/2024 - 20/03/2024
Barcelona, Spain
Congress
France Bioproduction Congress
03/04/2024 - 04/04/2024
Massy, France

Bioproduction last news

https://unsplash.com/photos/IFpQtennlj8
Antibodies, proteins, peptides
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the …

Attractive female doctor shaking a patient's hands in her office.
Not classified
RNA-Based Therapeutics: Past, Present and Future Prospects, Challenges in Cancer Treatment.

It is becoming more and harder in today’s climate to disregard the impact of cancer on social health. Even though …

Not classified
EC approves Vertex/CRISPR’s Casgevy gene therapy for inherited blood disorders – PMLiVE

[…] The European Commission (EC) has granted conditional marketing authorisation to Vertex Pharmaceuticals and CRI…

COBIOE partners